2023-09-28T16:06:26-05:00 2022-12-31 872525370 CITRIN COOPERMAN ADVISORS LLC 290 W MT PLEASANT AVENUE 3310 LIVINGSTON NJ 07039 990 2022-01-01 510181215 ISRAEL CANCER RESEARCH FUND INC ISRA 2129699800 52 VANDERBILT AVENUE 1410 NEW YORK NY 10017 RICHARD EDELHEIT TREASURER 2129699800 2023-09-22 1 RICHARD EDELHEIT 999009999 1 PAULA VUKSIC P00360739 9732180500 2023-09-22 3 AAL1 IAL1 2022 2023-04-26 12:10:37Z X RICHARD EDELHEIT 52 VANDERBILT AVENUE 1410 NEW YORK NY 10017 11046579 0 X WWW.ICRFONLINE.ORG X 1975 NY TO SUPPORT CANCER RESEARCH IN ISRAEL, FOR THE BENEFIT OF ISRAEL AND ALL MANKIND. 49 49 17 41 0 0 6953315 5860881 0 0 193187 176839 0 -303119 7146502 5734601 2795000 3306666 0 0 1794508 2083336 65532 0 1295994 756665 827605 5411705 6217607 1734797 -483006 17015756 16331164 2024230 2424170 14991526 13906994 X TO SUPPORT CANCER RESEARCH IN ISRAEL, FOR THE BENEFIT OF ISRAEL AND ALL MANKIND. 0 0 2976187 2406666 PROVIDE CANCER RESEARCH FUNDING FOR ISRAELI SCIENTISTS. ICRF IS THE LARGEST NON-PROFIT IN NORTH AMERICA DEDICATED TO SUPPORTING CANCER RESEARCH IN ISRAEL. OVER THE LAST 40 YEARS, ICRF HAS PROVIDED MORE THAN $87.5 MILLION TO SUPPORT CANCER RESEARCH IN ISRAEL, FUNDING OVER 2,700 RESEARCH PROJECTS AT ALL OF THE MAJOR ISRAELI RESEARCH INSTITUTIONS. TYPICALLY, 60-80 GRANTS ARE FUNDED ANNUALLY, BASED ON AN EVALUATION AND PRIORITIZATION BY INDEPENDENT REVIEW PANELS CONSISTING OF 40-50 LEADING CANCER SCIENTISTS FROM NORTH AMERICAN BIOMEDICAL RESEARCH CENTERS. ICRF GRANT CATEGORIES ARE TAILORED TO SUPPORT CANCER RESEARCHERS AT ALL OF THE VARIOUS STAGES OF THEIR CAREERS, AND WE ARE PROUD TO HAVE HELPED SUPPORT MANY OF TODAY'S MOST OUTSTANDING SCIENTISTS AT THE EARLIEST STAGES IN THEIR CAREERS. ICRF SEEKS TO CAPITALIZE ON THE SIGNIFICANTLY LOWER COSTS OF CONDUCTING CANCER RESEARCH IN ISRAEL. ALL AWARDS GO DIRECTLY TO THE DESIGNATED RESEARCHER WITHOUT ANY REDUCTION FOR OVERHEAD. IN 2021, WE AWARDED 49 RESEARCH GRANTS VALUED AT NEARLY $2.795M. 69646 50000 SUPPORT THE DEVELOPMENT OF THE NEXT GENERATION OF ISRAELI CANCER SCIENTISTS. ICRF IS COMMITTED TO FACILITATING THE DEVELOPMENT OF FUTURE CANCER SCIENTISTS IN ISRAEL. TOWARDS THIS END ICRF FUNDS THREE TYPES OF GRANTS: POSTDOCTORAL FELLOWSHIP AWARDS, RESEARCH CAREER DEVELOPMENT AWARDS, AND CLINICAL RESEARCH CAREER DEVELOPMENT AWARDS. FELLOWSHIPS SUPPORT MDS AND PHDS WHO HAVE JUST COMPLETED THEIR POSTGRADUATE TRAINING. THESE AWARDS CAN BE USED TO SUPPORT SALARIES OR RESEARCH COSTS, WHILE THESE INDIVIDUALS APPRENTICE IN THE LABORATORIES OF SENIOR INVESTIGATORS. CAREER DEVELOPMENT AWARDS ARE TO ENHANCE THE RESEARCH CAPABILITIES OF YOUNG ISRAELI SCIENTISTS IN THE FORMATIVE PHASE OF THEIR CAREERS. CANDIDATES MUST HAVE DEMONSTRATED OUTSTANDING POTENTIAL FOR CONTRIBUTIONS TO CANCER RESEARCH AND MUST EXHIBIT GREAT POTENTIAL TO BECOME INDEPENDENT INVESTIGATORS RESEARCH. SUPPORTING THESE NEWLY LAUNCHED SCIENTISTS, ENHANCES THEIR OPPORTUNITIES IN ISRAEL AND ALLOWS THEM TO OPTIMIZE THEIR WORK WITHOUT EMIGRATING TO OTHER ADVANCED COUNTRIES. 1183975 850000 SUPPORT COLLABORATIVE CANCER RESEARCH CONDUCTED BY ISRAELI SCIENTISTS IN ASSOCIATION WITH NORTH AMERICAN CANCER SCIENTISTS. CANCER SCIENCE OFTENTIMES REQUIRES MULTI-DISCIPLINARY APPROACHES, ENGAGEMENT WITH HIGHLY SPECIALIZED AREAS OF SCIENCE, AND EXPENSIVE EQUIPMENT THAT IS NOT EASILY ACCESSED. COLLABORATIONS BETWEEN SCIENTISTS IN ISRAEL AND NORTH AMERICA CAN ADDRESS THESE CHALLENGES, FOSTER UNEXPECTED SYNERGIES, AND ENHANCE BOTH INTELLECTUAL CURIOSITY AND INNOVATION. ICRF PROMOTES COLLABORATION BY SUPPORTING GRANTS THAT FUND PROMISING CANCER RESEARCH PROJECTS BEING CONDUCTED ON A COLLABORATIVE BASIS BETWEEN INVESTIGATORS IN ISRAEL AND AN AMERICAN OR CANADIAN RESEARCH INSTITUTION. 4229808 1 1 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 0 0 0 1 1 0 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 27 0 1 17 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 49 49 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 0 0 NY CA CT FL IL MD MA NJ OR PA VA CO GA KS ME MI NH NC DC OH RI TN SC WA X X TANIA ORENSTEIN 2129699800 52 VANDERBILT AVENUE 1410 NEW YORK NY 10017 DAVID ABRAMSON PRESIDENT 2.00 X X 0 0 0 BRYNA GOLDBERG CHAIR 2.00 X X 0 0 0 JOEL PELOFSKY FIRST VICE-PRESIDENT 2.00 X X 0 0 0 ROB DENSEN VICE-CHAIRMAN 2.00 X X 0 0 0 ARNOLD M BASKIES MD VICE PRESIDENT 2.00 X X 0 0 0 CHARLES BEN DAYAN VICE PRESIDENT 2.00 X X 0 0 0 JEFFREY BERNSTIEN VICE PRESIDENT 2.00 X X 0 0 0 RICHARD EDELHEIT TREASURER 2.00 X X 0 0 0 CYNTHIA PERL SECRETARY 2.00 X X 0 0 0 RICHARD LIPKIN EXECUTIVE COMMITTEE MEMBER 2.00 X 0 0 0 NANCY MAIZELS PHD EXECUTIVE COMMITTEE MEMBER 2.00 X 0 0 0 CHARLES SERLIN EXECUTIVE COMMITTEE MEMBER 2.00 X 0 0 0 ROBERT BARD TRUSTEE 2.00 X 0 0 0 BRUCE BARRON TRUSTEE 2.00 X 0 0 0 ALAN BERK TRUSTEE 2.00 X 0 0 0 JEFFREY BLY TRUSTEE 2.00 X 0 0 0 BENJAMIN BONAVIDA PHD TRUSTEE 2.00 X 0 0 0 LOUIS BRAUSE TRUSTEE 2.00 X 0 0 0 MICHELLE CHREIN TRUSTEE 2.00 X 0 0 0 STEVEN B COHEN TRUSTEE 2.00 X 0 0 0 MARSHA DEAKTER TRUSTEE 2.00 X 0 0 0 JORDANNA FEIFER TRUSTEE 2.00 X 0 0 0 VERA FINKELSTEIN TRUSTEE 2.00 X 0 0 0 BONNIE E FISH TRUSTEE 2.00 X 0 0 0 PAUL T FOX TRUSTEE 2.00 X 0 0 0 LESLIE FREEDMAN TRUSTEE 2.00 X 0 0 0 S DONALD FRIEDMAN TRUSTEE 2.00 X 0 0 0 TAMIR GILAT TRUSTEE 2.00 X 0 0 0 BRAD GOLDHAR TRUSTEE 2.00 X 0 0 0 KENNETH E GOODMAN TRUSTEE 2.00 X 0 0 0 GARY I GRAD MD TRUSTEE 2.00 X 0 0 0 ROBERT GREENE TRUSTEE 2.00 X 0 0 0 MARYANNE GREENFIELD TRUSTEE 2.00 X 0 0 0 LESLEY HELLER TRUSTEE 2.00 X 0 0 0 SAMUEL HERZFELD TRUSTEE 2.00 X 0 0 0 YASHAR HIRSHAUT MD TRUSTEE 2.00 X 0 0 0 MARK A ISRAEL MD TRUSTEE 2.00 X 0 0 0 IAN KADY TRUSTEE 2.00 X 0 0 0 BETH KAPLAN TRUSTEE 2.00 X 0 0 0 BARBARA KASELL TRUSTEE 2.00 X 0 0 0 SUSAN MATTESON KING TRUSTEE 2.00 X 0 0 0 MICHELLE MAKORI TRUSTEE 2.00 X 0 0 0 DAVID MALKIN MD TRUSTEE 2.00 X 0 0 0 LEN MARK TRUSTEE 2.00 X 0 0 0 PATRICK MUNDT TRUSTEE 2.00 X 0 0 0 LISA OVED TRUSTEE 2.00 X 0 0 0 TOM PELED TRUSTEE 2.00 X 0 0 0 GERELD SOFF MD TRUSTEE 2.00 X 0 0 0 SIDNEY J WINAWER MD TRUSTEE 2.00 X 0 0 0 BERYL CHERNOV NATIONAL EXECUTIVE DIRECTOR 40.00 X 342143 0 23861 CAITLIN SHMIDHEISER CHIEF DEVELOPMENT OFFICER 40.00 X 181227 0 5067 ALLYSON MARKS-GREENFIELD EXECUTIVE DIRECTOR, CHICAGO 40.00 X 176419 0 4305 ALAN HERMAN EXECUTIVE DIRECTOR, NEW YORK 40.00 X 209357 0 32079 TANIA ORENSTEIN CONTROLLER 40.00 X 157125 0 3163 DAVID KWESKIN CONNECTICUT DIRECTOR 40.00 X 113115 0 3697 1179386 0 72172 6 0 1 0 0 2048077 3812804 130163 5860881 182826 182826 4814295 4820282 -5987 -5987 -5987 188577 2048077 491696 -303119 -303119 5734601 0 0 -126280 3306666 3306666 523370 209348 104674 209348 1242742 356122 217144 669476 32229 12628 5495 14106 168679 66092 28758 73829 116316 35200 21666 59450 11105 10207 898 41680 38310 3370 129362 38158 24094 67110 28086 790 14939 12357 91542 9231 50640 31671 61096 6299 47796 7001 238336 76535 82610 79191 55532 29665 291 25576 41656 41656 106617 41182 22824 42611 BAD DEBT 20675 20675 MEALS AND ENTERTAINMENT 1918 236 1682 6217607 4229808 691805 1295994 1396320 1748907 1469319 712355 2050733 1805098 106975 76596 688727 223630 326337 465097 11617585 11471988 48487 51123 17015756 16331164 418309 412219 1340000 1518334 265921 493617 2024230 2424170 X 7669611 6774316 7321915 7132678 14991526 13906994 17015756 16331164 -483006 -601526 0 X X 0 1 X 1 0 X 4290202 7759750 4541503 6704934 5860881 29157270 4290202 7759750 4541503 6704934 5860881 29157270 4537420 24619850 120488 152685 161186 202683 182826 819868 4670 250 4920 29982058 787280 0.82120 0.83550 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER - 2018 AMOUNT: $ 4,670. 2019 AMOUNT: $ 250. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 3753296 -347307 3405989 3311782 441514 3753296 3032805 278977 3311782 2770993 261812 3032805 2753635 17358 2770993 0.21960 0.74850 0.03190 0 0 538514 95331 443183 30330 18089 12241 119883 110210 9673 465097 CAPITAL LEASE OBLIGATION 236038 OPERATING LEASE LIABILITY 257579 493617 X 5814748 -601526 378554 303119 80147 5734601 0 5734601 6899280 378554 303119 681673 6217607 0 6217607 PART V, LINE 4: TO SUPPORT CANCER RESEARCH IN ISRAEL, SUBJECT TO DONOR RESTRICTIONS. PART X, LINE 2: THE ORGANIZATION IS A NOT-FOR-PROFIT ORGANIZATION AND IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE, AND FROM STATE INCOME TAXES. THE ORGANIZATION RECOGNIZES AND MEASURES ITS UNRECOGNIZED TAX BENEFITS IN ACCORDANCE WITH FASB ASC 740, INCOME TAXES. UNDER THIS GUIDANCE, THE ORGANIZATION ASSESSES THE LIKELIHOOD, BASED ON THEIR TECHNICAL MERIT, THAT TAX POSITIONS WILL BE SUSTAINED UPON EXAMINATION BASED ON THE FACTS, CIRCUMSTANCES, AND INFORMATION AVAILABLE AT THE END OF EACH PERIOD. THE MEASUREMENT OF UNRECOGNIZED TAX BENEFITS IS ADJUSTED WHEN NEW INFORMATION IS AVAILABLE OR WHEN AN EVENT OCCURS THAT REQUIRES A CHANGE. MANAGEMENT HAS EVALUATED THE ORGANIZATION'S TAX POSITIONS AND HAS CONCLUDED THAT THE ORGANIZATION HAS TAKEN NO UNCERTAIN TAX POSITIONS THAT REQUIRE ADJUSTMENT TO THE FINANCIAL STATEMENTS. PART XI, LINE 2D - OTHER ADJUSTMENTS: SPECIAL EVENT EXPENSES 303,119. PART XII, LINE 2D - OTHER ADJUSTMENTS: SPECIAL EVENT EXPENSES 303,119. 1 MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, GRANTMAKING GRANTMAKING 3306666 0 0 0 0 0 0 3306666 0 3306666 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 743333 WIRE 0 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 520000 WIRE 0 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 385000 WIRE 0 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 325000 WIRE 0 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 290000 WIRE 0 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 265000 WIRE 0 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 198333 WIRE 0 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 175000 WIRE 0 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 60000 WIRE 0 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 50000 WIRE 0 MIDDLE EAST AND NORTH AFRICA CANCER RESEARCH 25000 WIRE 0 11 0 0 0 0 0 0 0 PART I, LINE 2: SCIENTISTS ARE REQUIRED TO PROVIDE REPORTS THAT SHOW THAT THEY COMPLIED WITH THE TERMS OF THE GRANTS FOR CANCER RESEARCH. PART III ACCOUNTING METHOD: X X X X X X 0 NY CA CT FL IL MD MA NJ OR PA VA CO GA KS ME MI NH NC DC OH RI TN SC WA NY TOWER OF HOPE GALA 816183 754983 61200 21175 37038 4213 98543 CHICAGO GALA 789568 737068 52500 7500 63226 1720 49988 10 630903 556026 74877 64126 56151 1428 86588 2236654 2048077 188577 92801 156415 7361 235119 491696 -303119 X X X 0 0 0 0 0 0 0 0 0 BERYL CHERNOV NATIONAL EXECUTIVE DIRECTOR 342143 0 0 0 0 0 0 0 23861 0 366004 0 0 0 ALAN HERMAN EXECUTIVE DIRECTOR, NEW YORK 209357 0 0 0 0 0 0 0 32079 0 241436 0 0 0 CAITLIN SHMIDHEISER CHIEF DEVELOPMENT OFFICER 181227 0 0 0 0 0 0 0 5067 0 186294 0 0 0 ALLYSON MARKS-GREENFIELD EXECUTIVE DIRECTOR, CHICAGO 176419 0 0 0 0 0 0 0 4305 0 180724 0 0 0 TANIA ORENSTEIN CONTROLLER 157125 0 0 0 0 0 0 0 3163 0 160288 0 0 0 X 6 130163 FMV 0 1 0 FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS REVIEWED BY THE TREASURER AND CONTROLLER AND DISTRIBUTED TO THE BOARD PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C MEMBERS OF THE BOARD, AS WELL AS ALL OFFICERS AND ALL EMPLOYEES, ARE REQUIRED TO SIGN WRITTEN CONFLICT OF INTEREST STATEMENTS ON AN ANNUAL BASIS. ANY CONFLICTS ARE DISCLOSED IN WRITING TO THE CHAIRPERSON OF THE BOARD AND APPROPRIATE ACTION IS TAKEN TO RESOLVE ANY CONFLICTS, INCLUDING REQUESTING THAT INTERESTED PERSON TO RECUSE THEMSELVES FROM VOTING AND PARTICIPATING IN THE BOARD DISCUSSIONS OF SUCH INTERESTS. A COPY OF EACH DISCLOSURE STATEMENT SHALL BE AVAILABLE TO ANY TRUSTEE OF THE ORGANIZATION UPON REQUEST. FORM 990, PART VI, SECTION B, LINE 15A EXECUTIVE COMMITTEE MEMBERS ARE INVOLVED IN THE DECISION MAKING PROCESS ON THE COMPENSATION OF THE EXECUTIVE DIRECTOR. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S AUDITED FINANCIAL STATEMENTS ARE AVAILABLE TO THE GENERAL PUBLIC ON THE ORGANIZATION WEBSITE AND UPON REQUEST. FORM 990, PART XII, LINE 2C: THE ORGANIZATION'S OVERSIGHT PROCESS AND SELECTION PROCESS DID NOT CHANGE DURING THE YEAR.